BioVie’s bezisterim improves Parkinson’s symptoms in patients with elevated inflammation in Phase 2 trial
BIVI•BioVie presented results from a 57-patient Phase 2 trial of bezisterim in early Parkinson’s disease. Patients with higher baseline inflammation had statistically significant improvements in motor and non-motor symptoms compared with placebo.
1. Phase 2 trial results
BioVie presented results from its 12-week, placebo-controlled SUNRISE-PD trial at the American Neurological Association meeting held October 17-20, 2026. Overall efficacy outcomes generally favored bezisterim, while patients with higher baseline inflammation showed statistically significant improvements in motor and non-motor symptoms compared with placebo. Bezisterim was well tolerated, with fewer treatment-emergent adverse events than placebo; neither group reported severe or serious adverse events.
